Limits...
Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients.

Urakawa H, Tsukushi S, Sugiura H, Yamada K, Yamada Y, Kozawa E, Arai E, Futamura N, Ishiguro N, Nishida Y - Oncol Lett (2014)

Bottom Line: The treatment efficacy and side-effects were evaluated.Major grade 3 or 4 side-effects included leukopenia in 14 cases, anemia in seven, thrombocytopenia in three, nausea in two and febrile neutropenia in two.The estimated five-year OS rate in this study was acceptable in patients without metastasis prior to treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Aichi 466-8550, Japan.

ABSTRACT
The present study investigated the safety and efficacy of neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcoma in adult and older patients. A total of 18 consecutive patients with bone sarcoma (American Joint Committee on Cancer stage II in 14 patients and stage IV in four) treated with neoadjuvant and adjuvant chemotherapy at Nagoya Musculoskeletal Oncology Group hospitals in Japan between 2004 and 2011 were reviewed. The treatment efficacy and side-effects were evaluated. The responses to neoadjuvant chemotherapy were stable disease in 11 patients and progressive disease in three. Among the 12 evaluable patients, there were five with ≥90% tumor necrosis. The estimated overall survival (OS) rate at five years for the patients without metastasis prior to treatment was 56%. Major grade 3 or 4 side-effects included leukopenia in 14 cases, anemia in seven, thrombocytopenia in three, nausea in two and febrile neutropenia in two. One patient discontinued chemotherapy due to a temporarily depressed level of consciousness with arrhythmia (grade 2). The estimated five-year OS rate in this study was acceptable in patients without metastasis prior to treatment. A better coordinated prospective study of this combination regimen for older patients with bone sarcoma will be required to clarify its efficacy and tolerability.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier estimated overall survival for 14 osteosarcoma patients without metastasis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214507&req=5

f1-ol-08-06-2485: Kaplan-Meier estimated overall survival for 14 osteosarcoma patients without metastasis.

Mentions: Evaluation with RECIST for the treatment site showed that the responses following neoadjuvant chemotherapy, with a median number cycles of 3.5 (range, 1–5), were stable disease (SD) in 11 cases (79%) and progressive disease (PD) in three (21%) (Table II). Of the 12 patients with SD and PD, there were five (42%) with tumor necrosis of ≥90% (Table II). The final status was no evidence of disease in nine cases (50%), alive without disease in two (11%) and dead of disease in seven (39%), at a median follow-up time of 18.0 months (range, 4.6–73.7 months) (Table II). Estimated five-year OS rates for patients without and with metastasis prior to treatment were 56% (Fig. 1) and 25% (Fig. 2), respectively (Table II). Estimated two-year OS rates for patients without metastasis were 100% in patients aged <60 years, and 54% in patients >60 years (P=0.072 between the two groups) (Fig. 3).


Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients.

Urakawa H, Tsukushi S, Sugiura H, Yamada K, Yamada Y, Kozawa E, Arai E, Futamura N, Ishiguro N, Nishida Y - Oncol Lett (2014)

Kaplan-Meier estimated overall survival for 14 osteosarcoma patients without metastasis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214507&req=5

f1-ol-08-06-2485: Kaplan-Meier estimated overall survival for 14 osteosarcoma patients without metastasis.
Mentions: Evaluation with RECIST for the treatment site showed that the responses following neoadjuvant chemotherapy, with a median number cycles of 3.5 (range, 1–5), were stable disease (SD) in 11 cases (79%) and progressive disease (PD) in three (21%) (Table II). Of the 12 patients with SD and PD, there were five (42%) with tumor necrosis of ≥90% (Table II). The final status was no evidence of disease in nine cases (50%), alive without disease in two (11%) and dead of disease in seven (39%), at a median follow-up time of 18.0 months (range, 4.6–73.7 months) (Table II). Estimated five-year OS rates for patients without and with metastasis prior to treatment were 56% (Fig. 1) and 25% (Fig. 2), respectively (Table II). Estimated two-year OS rates for patients without metastasis were 100% in patients aged <60 years, and 54% in patients >60 years (P=0.072 between the two groups) (Fig. 3).

Bottom Line: The treatment efficacy and side-effects were evaluated.Major grade 3 or 4 side-effects included leukopenia in 14 cases, anemia in seven, thrombocytopenia in three, nausea in two and febrile neutropenia in two.The estimated five-year OS rate in this study was acceptable in patients without metastasis prior to treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Aichi 466-8550, Japan.

ABSTRACT
The present study investigated the safety and efficacy of neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcoma in adult and older patients. A total of 18 consecutive patients with bone sarcoma (American Joint Committee on Cancer stage II in 14 patients and stage IV in four) treated with neoadjuvant and adjuvant chemotherapy at Nagoya Musculoskeletal Oncology Group hospitals in Japan between 2004 and 2011 were reviewed. The treatment efficacy and side-effects were evaluated. The responses to neoadjuvant chemotherapy were stable disease in 11 patients and progressive disease in three. Among the 12 evaluable patients, there were five with ≥90% tumor necrosis. The estimated overall survival (OS) rate at five years for the patients without metastasis prior to treatment was 56%. Major grade 3 or 4 side-effects included leukopenia in 14 cases, anemia in seven, thrombocytopenia in three, nausea in two and febrile neutropenia in two. One patient discontinued chemotherapy due to a temporarily depressed level of consciousness with arrhythmia (grade 2). The estimated five-year OS rate in this study was acceptable in patients without metastasis prior to treatment. A better coordinated prospective study of this combination regimen for older patients with bone sarcoma will be required to clarify its efficacy and tolerability.

No MeSH data available.


Related in: MedlinePlus